- Home
- SNDX vs PDM Comparison
SNDX vs PDM Comparison
Compare SNDX & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- PDM
- Stock Information
- Founded
- SNDX 2005
- PDM 1997
- Country
- SNDX United States
- PDM United States
- Employees
- SNDX N/A
- PDM N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- PDM Building operators
- Sector
- SNDX Health Care
- PDM Real Estate
- Exchange
- SNDX Nasdaq
- PDM Nasdaq
- Market Cap
- SNDX 1.1B
- PDM 921.9M
- IPO Year
- SNDX 2016
- PDM N/A
- Fundamental
- Price
- SNDX $9.60
- PDM $7.61
- Analyst Decision
- SNDX Strong Buy
- PDM Buy
- Analyst Count
- SNDX 11
- PDM 5
- Target Price
- SNDX $34.18
- PDM $9.40
- AVG Volume (30 Days)
- SNDX 2.0M
- PDM 950.3K
- Earning Date
- SNDX 07-31-2025
- PDM 07-28-2025
- Dividend Yield
- SNDX N/A
- PDM 6.52%
- EPS Growth
- SNDX N/A
- PDM N/A
- EPS
- SNDX N/A
- PDM N/A
- Revenue
- SNDX $43,722,000.00
- PDM $568,472,000.00
- Revenue This Year
- SNDX $426.77
- PDM $0.50
- Revenue Next Year
- SNDX $98.31
- PDM N/A
- P/E Ratio
- SNDX N/A
- PDM N/A
- Revenue Growth
- SNDX N/A
- PDM N/A
- 52 Week Low
- SNDX $8.58
- PDM $5.46
- 52 Week High
- SNDX $25.07
- PDM $11.12
- Technical
- Relative Strength Index (RSI)
- SNDX 48.99
- PDM 59.27
- Support Level
- SNDX $8.59
- PDM $7.33
- Resistance Level
- SNDX $10.01
- PDM $7.71
- Average True Range (ATR)
- SNDX 0.54
- PDM 0.22
- MACD
- SNDX 0.10
- PDM 0.01
- Stochastic Oscillator
- SNDX 71.48
- PDM 84.38
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.